Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou do not have to wean yourself off Mounjaro in the way you would taper a steroid or certain antidepressants. Mounjaro (tirzepatide) does not cause physical dependence, and there is no clinically required dose-reduction schedule before stopping. If you and your prescriber decide to discontinue, you simply stop — though how and when to do that is always a conversation worth having with a clinician, because stopping without a plan can mean regaining weight quickly. Mounjaro is a prescription-only medicine for weight management in adults, assessed and supervised by a GPhC-registered prescriber, and any decision to stop should sit within that clinical relationship rather than being made unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
No. The Mounjaro prescribing information (the Summary of Product Characteristics published on the Electronic Medicines Compendium) does not include a tapering or dose-reduction requirement before discontinuation. Tirzepatide does not bind to receptors in a way that creates the kind of physiological dependence associated with medicines that need a slow withdrawal. When the last injection's effects wear off (roughly over the following week or two, given Mounjaro's half-life), the body simply returns to how it functioned before treatment began.
That said, "no tapering required" is not the same as "stop without thinking about it". The question of how to wean yourself off Mounjaro, or whether to at all, deserves a proper clinical conversation. Your prescriber can look at where you are in treatment, what your weight-management plan looks like going forward, and whether pausing or stopping is actually in your interest right now. That is a different thing from a pharmacological taper.
If you are curious about what a planned break looks like in practice, our page on taking a week off Mounjaro covers the shorter-term picture.
This is the part people most need to understand. The NHS tirzepatide page is clear that weight management medicines work while you take them, they are not a course that trains your body to keep the weight off permanently once you finish. The appetite-suppressing, gastric-emptying effects of tirzepatide reverse as the medicine clears your system. For many people, hunger gradually returns to pre-treatment levels, and weight can come back, sometimes relatively quickly.
Clinical trials have consistently shown this pattern across GLP-1 and dual-agonist medicines. It does not mean the treatment failed; it reflects the biology of obesity as a chronic condition. The NHS describes obesity as a long-term health issue rather than a short-term problem to be fixed and left behind, and medicines for it tend to follow that logic.
How fast any regain happens varies. Factors include how much lifestyle change you have embedded alongside treatment, your starting metabolic picture, and how long you were on the medicine. Tracking your weight thoughtfully while still on treatment (and having a plan for when you stop) matters. For practical guidance on how often to check, see our page on weighing yourself during Mounjaro treatment.
Yes, and this is the most useful thing to take away from this page. There is no harm from simply stopping, no dangerous withdrawal, no rebound that requires medical management in the same way as some other medicines. But the decision sits within a clinical relationship for a reason.
A prescriber can help you time a stop sensibly: for example, not in the middle of a particularly high-stress period, not when you have only just increased your dose and your system is still settling, and not without at least a working plan for maintaining the habits built during treatment. They can also discuss whether stopping is actually what you want, or whether a pause (say, during surgery or a period where injections are not practical) is closer to what you are looking for. Our page on whether you need to wean off Mounjaro covers some of the nuance around timing and clinical context.
If cost is part of the reason you are thinking about stopping, it is worth knowing what the full picture looks like before deciding. Our Mounjaro price comparison guide lays out the honest market context. One transparent price (consultation, prescription, aftercare) can sometimes make continuing more straightforward than people expect.
Restarting is possible and reasonably common. There is no clinical rule that prevents it. If you have been off treatment for a while, your prescriber will typically want to restart from the beginning of the titration schedule rather than picking up at the dose you left off. This is a tolerability precaution, not a punishment, starting again at the full maintenance dose after a gap significantly increases the chance of GI side effects.
At nume, every repeat order goes through a fresh clinical review before anything is dispensed. That means if you have had a break and want to restart, a prescriber reads your updated details before your pen is sent. Your order arrives via DPD the next working day, in plain packaging, tracked to your door, the same process whether it is your first pen or your return to treatment.
For a broader look at how tirzepatide works and what the treatment journey typically involves, the tirzepatide overview on our site is a good starting point. And if you have questions our team can help with directly, the contact page is the quickest route.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.